PONVORY
As listed in the register: PONVORY
20 mg · tablet
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Ponesimod
- Made by
- Vanda Pharmaceuticals Inc.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (PONVORY). It describes the substance, not this exact product.
Ponesimod is a S1P receptor 1 modulator that binds with high affinity to S1P receptor 1.
Ponesimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood.
Ponesimod is extensively metabolized prior to excretion in humans, though unchanged ponesimod was the main circulating component in plasma.
Food Effect Food does not have a clinically relevant effect on ponesimod pharmacokinetics; therefore, PONVORY may be taken with or without food.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-12-04
Safety of the active substance
From the US prescribing label for the same active substance (PONVORY). It describes the substance, not this exact product.
The most common adverse reactions (incidence at least 10%) in PONVORY-treated patients in Study 1 were upper respiratory tract infection, hepatic transaminase elevation, and hypertension.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States2 matching products
European UnionNo exact match for this strength and form
Spain1 matching products
Netherlands1 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Vanda Pharmaceuticals Inc. |
|---|---|
| Active substance | Ponesimod |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 20 mg |
| Form | tablet |
| Classification | L04AE04 · Cancer treatments and immune-system medicines |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02515482 |
| DPD drug code | 100487 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- tablet2 products